141 results
8-K
EX-10.1
ADAP
Adaptimmune Therapeutics Plc
11 Jun 24
Departure of Directors or Certain Officers
4:15pm
to receive severance benefits following termination of employment under certain conditions. The purpose of the Policy is to attract and retain qualified
8-K
EX-10.1
5de w4vzq3
27 Feb 24
Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company’s Sarcoma Franchise
8:13am
S-8
EX-5.1
d4l7u8 5xr3wi
30 Nov 23
Registration of securities for employees
4:16pm
S-8
svf2 b2c82b0
30 Nov 23
Registration of securities for employees
4:16pm
S-8
9e1axm8s6 su
30 Nov 23
Registration of securities for employees
4:16pm
8-K/A
EX-99.3
bu2to3o5p4 anpoy533
10 Aug 23
Financial Statements and Exhibits
4:05pm
8-K
EX-10.1
r5ygri3
29 Jun 23
Departure of Directors or Certain Officers
4:25pm
8-K
EX-10.2
w5vnnp68cx
29 Jun 23
Departure of Directors or Certain Officers
4:25pm
8-K
EX-10.2
lm6 9m8vj31
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
8-K
EX-10.3
mmp44gn6p m9c
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
8-K
EX-10.4
shzez1 dvu
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
424B3
0eip5mk
20 Apr 23
Prospectus supplement
4:32pm
S-4/A
EX-99.3
8cm1tsa
18 Apr 23
Registration of securities issued in business combination transactions (amended)
4:01pm
S-4/A
EX-5.1
ner uy2ny95
18 Apr 23
Registration of securities issued in business combination transactions (amended)
4:01pm